ノバルティスのインスタグラム(novartis) - 6月1日 00時01分

“How do we smartly combine our drugs for patients? Answering this question is the goal of our program,” says Catherine Sabatos-Peyton, an immunologist at the Novartis Institutes for BioMedical Research (NIBR). Immunotherapies have been life-changing for patients who respond to them, but overall only ~20% of patients respond. In an attempt to expand immunotherapy reach, approx.1100 clinical trials have been launched by companies and research institutions to test these medicines in a range of combinations. This shotgun approach to combination therapy isn’t sustainable. So researchers at Novartis have launched a comprehensive research program designed to systematically inform the selection of smart combination therapies. By going beyond current assumptions about how cancer therapies work, we aim to move towards a scientifically guided rationale for choosing smart combinations of cancer therapies. #ASCO18

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する